The role of p23 in breast cancer has been extensively studied by the Garabedian laboratory, who showed p23 enhances cell motility and that higher levels correlate with poor prognosis and a reduction in disease‐free survival time in breast cancer patients (Oxelmark et al., 2006, 2012, 2010). This evidence concerns the gene PTGES3 and breast cancer.